18 November 2009 (PublicWire) — PanGenex Corporation (PKS.PGCX) has finalized a strategic partnership with BulovaTech Labs, Inc., a wholly-owned subsidiary of Bulova Technologies Group Inc., (PKS.BLVT). The partnership was put together to support the joint development and commercialization of PanGenex’s nutraceutical and healthcare products. Included in the partnership is an exclusive collaboration agreement that will accelerate the development of proprietary technologies and products, which will be marketed by PanGenex corp under the PanGenex trademark.
PanGenex is a publicly traded corporation (PINK SHEETS: PGCX) and pursues business opportunities in the $70 billion dollar nutraceutical and dietary supplement industry. With a focus specifically on the cardiovascular health segment, PanGenex develops and markets sector leading, patented or patent pending, condition specific nutraceuticals and topical over-the-counter (OTC) drugs and personal care products.
About Bulova Technologies Group
Bulova Technologies Group Inc., formerly Vital2 Corporation, provides interactive tools, which analyzes, categorizes, prioritizes, identifies, and tailors information into knowledge, based on individual or corporate requirements. The Company’s solution incorporates data mining capabilities with the ability to extract data from any source. It can render data in near real-time, and provides dynamic and static reporting through dashboard capabilities and traditional reporting, all in a secure environment.